New research has revealed that a treatment called Stem Cell Educator therapy is safe and effective for treating type 1 and type 2 diabetes.
In the therapy, the patient's immune cells cultures with cord blood stem cells and returns only the "educated" immune cells to the patient's circulation.
The strategy is believed to provide benefits because abnormalities in multiple types of immune cells contribute to the autoimmunity in type1diabetes and the insulin resistance in type 2 diabetes.
Dr YongZhao, lead author of the study said, "Current mechanistic studies demonstrated that platelets and their released mitochondria may contribute to the long-lasting clinical improvement of islet beta cell function in type 1 and 2 diabetic patients after Stem Cell Educator therapy."
He added, "This therapy can also be applied to treat other autoimmune and inflammation-related diseases."
.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
